Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz in Early Alzheimer’s Disease (Phase 2a)
2023-509613-37-01Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Efavirenz with Placebo (2 arms). Primary endpoint: Change From Baseline Levels in 24-hydroxycholesterol in cerebrospinal fluid. Planned start Jun 2024; status: authorised.
02
Drugs
efavirenz
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-509613-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509613-37-01.